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Editorial on the Research Topic
Immunity to Human Fungal Pathogens: Mechanisms of Host Recognition, Protection,
Pathology, and Fungal Interference
Fungi are eukaryotic heterotrophs present in virtually every environment, with potentially more
than 5 million individual species (1). Despite this impressive biodiversity, only about 300 species
are capable of causing disease in humans (2). The most successful human pathogens among
these share the ability to grow at the physiologic temperature of endothermic vertebrates and
consequently colonize or infect only susceptible hosts (3). Immune-competent humans are largely
resistant to fungal infections that throughout much of human history were considered rare and
remained poorly understood. However, since 1980, the prevalence of opportunistic fungal diseases
has steadily increased in parallel with increases in individuals with acquired immune deficiencies or
those receiving immune suppressive or myeloablative therapies (4–6). Worse yet, current options
for antifungal therapies remain limited and the continued emergence of resistant strains threatens
to further erode antifungal drug efficacy (7, 8). The pressing need for novel therapies has thus
resulted in increasing interest in studies in fungal biology and host-fungal interactions that may
identify novel antifungal targets or alternative antifungal therapies.
The constant exposure of humans to both commensal and environmental fungi requires a
competent immune system for tolerance, protection, and/or clearance, while limiting collateral
damage caused by excessive or detrimental inflammation. Innate responses to fungal pathogens
are initiated by fungal component recognition via an array of pathogen-associated molecular
pattern recognition receptors (PRRs) (9–11). Recognition of fungal ligands by these receptors
initiates a cascade of signaling events that result in activation of inflammatory cytokine and
chemokine expression, driving recruitment and activation of innate phagocytic cells such as
neutrophils and monocytes to the site of infection. Dendritic cells take up fungal particles
in this cytokine-rich microenvironment, integrate these activating signals through PRRs and
cytokine/chemokine receptors, migrate to site-draining lymph nodes, and subsequently activate
naïve fungal-specific T cells. In this manner, early fungal recognition and inflammation
provide critical signals that drive adaptive antifungal immunity. However, significant variation
encountered by the host innate immune system, and co-evolutionary adaptation of pathogenic
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fungi, drive diverse disease outcomes ranging from tolerance,
clearance and resolution to dissemination and excessive
inflammation.
Increased understanding of these host-fungal interactions and
the mechanisms that favor protective immunity over immune
pathology could provide targets for novel therapeutic approaches
that complement the limited repertoire of existing antifungal
drugs. The aim of this research topic is to explore the host and
fungal pathways that program innate and adaptive immunity
and the immune cells, molecules, and regulatory pathways that
comprise protective or detrimental responses to fungal exposure
or infection. Researchers from 15 countries in North and South
America, Europe, Asia, and Australia contributed 36 review
and original research articles that cover a wide range of fungal
pathogens, disease models, and effector and regulatory cell
and molecular pathways of host immune responses to fungal
exposure and infection. Here, we present an outline of the
findings, perspectives, and reviews contained in this research
topic.
The major class of pattern recognition receptors, the C-
type lectin receptors (CLRs), including molecules critical for
the initiation of inflammation and the development of adaptive
immunity to fungi, are reviewed by Tang et al.. Although the
important role of the β-1,3-glucan receptor dectin-1 in antifungal
immunity is well appreciated, the α-mannan-binding dectin-
2 and dectin-3 also influence responses to fungal exposure
and infection and their roles are less clear. In support of
these studies, Preite et al. show that dectin-2 and dectin-3
mediate antifungal activity and cytokine secretion of human
plasmacytoid dendritic cells (pDCs) in response to the endemic
dimorphic fungal pathogen Paracoccidioides brasiliensis via a
pathway mediated by the CLR-associated signaling molecule Syk.
In addition, de Castro et al. show that mouse bone marrow-
derived macrophages (BMMs) and DCs (BMDCs) produce IL-
1β and IL-18 in response to Fonsecaea pedrosoi, the main
causative agent of chromoblastomycosis, in a dectin−1, −2,
and −3-dependent manner. A role for the NOD-Like Receptor
P3 (NLRP3), an intracellular protein complex that controls
activation of inflammatory caspases and cytokine production,
is shown by Feriotti et al. as important for the development of
protective immunity to pulmonary infection with P. brasiliensis.
β-glucan stimulation of NLRP3 inflammasome-mediated IL-1β
secretion in B cells reported by Ali et al. shows innate antifungal
cytokine production in an adaptive lymphocytes that were also
capable of producing IgM in an NLRP3-dependent manner.
In contrast to the protective role for the NLRP3
inflammasome in invasive infection with the filamentous
opportunistic mold Aspergillus fumigatus (12), Gresnigt et al.
report that NOD1-deficient mice exhibit increased protection
from invasive aspergillosis compared to wild-type controls.
Another potential fungal PRR is the fibrinogen-binding domain
receptor FIBCD1, and Schoeler Jepsen et al. demonstrate
suppression of IL-8 secretion, mucin production, and airway
inflammatory gene transcription in FIBCD1-transfected
human lung epithelial cells in response to A. fumigatus. Lung
epithelial cells are shown by Hayes et al. to produce IL-8
and MCP-1 in response to the Alternaria allergen Alt a 1
in a TLR2/4-dependent manner. Collectively, these studies
support fungal pattern recognition by an increasing number
of receptor families with diverse roles in the development of
protective or detrimental immunity to fungal exposure and
infection.
PRR-expressing tissue-resident macrophages are part of
the first line of defense against fungal infections (reviewed by
Xu and Shinohara). Circulating monocytes are subsequently
recruited to sites of infection in response to inflammatory
signals produced by tissue-resident macrophages. Tóth et
al. report that the exposure of hyphae of the dematiaceous
mold Curvularia lunata to human THP-1 monocytes
resulted in increased inflammatory IL-8 and regulatory/anti-
inflammatory IL-10, suggesting a possible mechanism for
the ability of this species to cause chronic infections in
immune competent individuals. Landgraf et al. report that
dihydrolipoyl dehydrogenase secreted by P. brasiliensis may
act as an exoantigen that enhances macrophage phagocytosis.
Mukaremera et al. report that hypha of the yeast Candida
albicans induced low levels of cytokine secretion from
human monocytes, with the highest levels from yeast and
intermediate levels from pseudohypha, and cell wall mannan
depletion partially reversed these responses. Using fluorescence
yeast cell wall-labeling to measure yeast division within
macrophages, Dagher et al. show that activation of the
tyrosine kinase Syk is critical for macrophage control of
phagocytosed C. glabrata. Together, these studies provide new
insights into the roles for monocytes and macrophages in
induction and regulation of antifungal inflammation and fungal
clearance.
Inflammatory cytokine production by macrophages leads to
localized inflammation with production of chemokines that
attract additional innate immune cells. Caffrey-Carr et al.
report that antifungal protection and recruitment of neutrophils
and eosinophils in response to A. fumigatus inhalation is
dependent on the lipid inflammatory mediator Leukotriene
β4. Clark et al. show that a key mediator of chromatin
decondensation, protein deaminase 4, and the complement
receptor CR3, are critical for neutrophil extracellular trap
formation in response to A. fumigatus, while hyphal killing
required only CR3. The role of innate lymphoid natural killer
(NK) cells in innate antifungal immunity is reviewed by Schmidt
et al.. These works further illustrate diverse mechanisms and
roles for innate myeloid and lymphoid cells in antifungal
immunity.
Dendritic cells (DCs) are multifaceted professional antigen
presenting cells that integrate antigen uptake and local
inflammatory signals in order to effectively prime adaptive
antifungal immune responses upon migration to site-draining
lymph nodes (9). The role of type I interferon-producing
plasmacytoid DCs in antifungal immunity in the context
of chronic HIV infection is reviewed by Maldonado and
Fitzgerald-Bocarsly. Xu et al. investigated the role of macrophage
receptor with collagenous structure (MARCO) on pDC
recruitment and induction of antifungal adaptive immunity to
C. neoformans infection, and report that expression of MARCO
promoted recruitment of lymph node DCs and skewed local
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and systemic T helper cell responses away from protective Th1
responses and toward non-protective Th2 responses. Wong et al.
demonstrate a role for leucine-rich repeat kinase 2 (LRRK2) in
translocation of NFAT to the nucleus in DCs in the early stages of
the non-canonical autophagic response to A. fumigatus conidia,
thus connecting LRRK2 with NFAT-mediated IL-2 expression
in early antifungal immunity. Hellmann et al. compared
immune responses to A. fumigatus in human and mouse DCs,
macrophages, and neutrophils, and observed that human DCs
exhibited more significant increases in maturation markers and
phagocytic ability than murine DCs, while murine neutrophils
and macrophages displayed more reactive oxygen species
production after A. fumigatus exposure. Collectively, these works
provide support for additional mediators of DC function that
shape antifungal adaptive immunity, and suggest distinct roles
for these cells in human fungal disease and experimental animal
models.
After DCs migrate to draining lymph nodes, they present
fungal antigen to naïve T cells, inducing antifungal adaptive
immunity. This process is influenced by cytokines in the
microenvironment. Formation of the antifungal Th17 subset
of T helper cells is promoted by the inflammatory cytokines
IL-6 and IL-23, and Tristão et al. report that these cytokines,
along with the IL-17 receptor A, were necessary for protective
lung granuloma formation in mice infected with P. brasiliensis.
IL-1α/β also influence adaptive immune responses to fungi,
such as the dimorphic Cryptococcus spp., as Shourian et
al. observed that IL-1 receptor type 1-deficient mice had
increased cryptococcal burden, eosinophilia, M2 macrophage
polarization, and recruitment of CD4+IL-13+ T cells, with
a concomitant reduction in pro-inflammatory Th1 and Th17
cytokines. However, excessive inflammation and Th1 activation
in C. neoformans infection is also detrimental, and was reported
by Fa et al. to be mediated by the cell death regulatory genes
FADD (Fas-associated death domain) and RIP3K (receptor
interacting protein kinase 3). The results of these studies support
roles for Th1 and Th17 responses in antifungal immunity, as well
as a requirement for regulation of cell death to limit excessive
inflammation.
Cell and molecular regulation of immunity occurs at multiple
levels from induction to resolution of immune responses. An
enzyme that limits available tryptophan and thus dampens
immune cell proliferation and effector function, indoleamine
2,3-dioxygenase (IDO), is produced by mammalian hosts
and the fungal pathogen A. fumigatus; findings that shed
light on this host-pathogen dynamic are reviewed by Choera
et al.. De Araújo et al. report that DCs from an infected
P. brasiliensis-susceptible mouse strain exhibit IDO activity
and promote inflammation, while DCs from resistant mice
phosphorylate IDO and promote a tolerogenic phenotype. The
same group further compared P. brasiliensis infection in IDO-
deficient and wild-type mice, and observed increased mortality,
fungal burden, histopathology, and Th17 cell recruitment and
activation in IDO-deficient mice with concomitant decreases
in Th1 and Treg cells de Araújo et al.. In addition to the
enzymatic activity and signaling by IDO, antifungal immune
responses are regulated at the post-transcriptional level by
microRNAs (miRNAs); these molecules and their associated
pathways are reviewed by Croston et al.. Zimmerman et al.
report that patients with autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) exhibit decreased
levels of the signaling molecule STAT1, in contrast with
patients with STAT1 gain-of-function mutations, despite
similar disease phenotypes. These works highlight findings
of enzymatic, post-translational, and signal transduction in
the regulation of antifungal immunity and fungal disease
susceptibility.
Although spore/hyphal recognition by innate cells drives
the development of immunity to fungal pathogens, host-fungal
pathogen interactions are also considered at the macroscopic
level of microbial communities (e.g., biofilms) and host tissues.
Kernien et al. review host immune recognition of fungal
biofilms and biofilm properties that inhibit host recognition and
clearance. Zhang et al. explore how immune interactions
with respiratory and gastrointestinal fungal microbiota
contribute to chronic airway inflammatory disease. Sparber
and LeibundGut-Landmann more specifically discuss host
immune responses to skin-colonizing Malassezia species,
yeasts that are involved in a variety of skin disorders. Finally,
Casadevall et al. review the evidence that C. neoformansmediates
host damage at the molecular, cellular, tissue, and organism
levels, in some instances with formation of large fungal masses
in brain tissue. These reviews highlight emerging areas of
fungal immunology that consider fungal interactions with the
host immune system beyond the level of cell and molecular
recognition.
Despite significant advances in our understanding of host
immunity to fungal exposure and infection, treatment of
fungal diseases has not progressed beyond the use of a
limited repertoire of antifungal drugs that are rendered
increasingly ineffective by emerging fungal resistance. Since
appropriate antifungal immunity is critical for protection from
fungal disease, complementary therapies that target immune
pathways represent areas of considerable interest for fungal
immunologists. Elsegeiny et al. review studies of immune
pathology in cryptococcal infection and discuss the need for
immune targeting therapies that suppress immune-mediated
damage without further compromising host protection. Van
Dyke et al. demonstrate that combining non-lethalC. neoformans
challenge with local IFN-γ production elicits an immune
response that protects mice from subsequent lethal infection.
Tso et al. summarize efforts and obstacles in the development
of anti-Candida vaccines, and discuss the potential use of
trained immunity in the development of strategies against
opportunistic fungal infections. Finally, Kumaresan et al. review
the development of CD8+ T cell therapy for the control of
invasive fungal infections, with a focus on the use of chimeric
antigen receptor (CAR) T cells that target β-glucan. These
reviews underscore the importance of current and future efforts
to enhance immune protection while limiting immune pathology
in patients that may not respond to traditional antifungal
therapies.
Collectively, the studies described in original research
and review articles in this topic provide optimism
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for the future of antifungal immune therapy. Recent
advances by fungal immunologists have greatly increased
our understanding of the basic mechanisms of innate
immune recognition, inflammation, adaptive immunity,
and regulation of antifungal immune responses at
molecular, cell, tissue, and organismal levels. We hope
these articles will stimulate further research with the
ultimate goal of improving outcomes for patients with fungal
diseases.
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